Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10080871 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL336867 | 0.84 | ALDH1A1 (0.41) | ALDH1A1KDM4ECYP2C19MAPTCYP3A4 | |
| SCHEMBL336472 | 0.79 | EGLN1 (0.55) | HIF1A | |
| SCHEMBL337027 | 0.78 | ALDH1A1 (0.39) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL2436234 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4ECYP2C19MEN1KMT2A | |
| SCHEMBL337399 | 0.77 | HIF1A (0.45) | MEN1KMT2AHIF1A | |
| SCHEMBL2434416 | 0.75 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL336366 | 0.73 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL2579380 | 0.72 | ALDH1A1 (0.45) | ALDH1A1KDM4EHPGDHIF1A | |
| SCHEMBL2577076 | 0.72 | ALDH1A1 (0.40) | ALDH1A1KDM4EMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2155746-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008137084-A2 | DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | EGLN3, EGLN2, HIF1AN | ALDH1A1 108/4885KDM4E 248/4885CYP2C19 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.